Search clinical trials for: Lenvatinib plus TACE

Total 8199 results

Yunfei Yuan

Recruiting

TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial (Thalen)

Hepatocellular Carcinoma | Transarterial Chemoembolization

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Fudan University

Recruiting

PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

Hepatocellular Carcinoma

China
Guangxi Medical University

Recruiting

DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

Cholangiocarcinoma Non-resectable

China
Peking University Cancer Hospital & Institute

Not yet recruiting

cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC

HCC | Regorafenib | Transarterial Chemoembolization | Hepatic Arterial Infusion Chemotherapy
Peking Union Medical College Hospital

Recruiting

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Hepatocellular Carcinoma

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
Wuhan Union Hospital, China

Recruiting

The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study

Hepatocellular Carcinoma

China
Fudan University

Active, not recruiting

Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
AstraZeneca

Recruiting

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (EMERALD-3)

Hepatocellular Carcinoma

Spain, Canada, Germany, Belgium, United States, France, Italy, Japan, China, Egypt, India, Russian Federation, Taiwan, Vietnam, Thailand, Saudi Arabia, Portugal, Korea, Republic of, Brazil, Malaysia, Mexico, Philippines, Puerto Rico
Sichuan University

Not yet recruiting

The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Carrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Recruiting

A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC

Hepatocellular Carcinoma | Donafenib

China
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

Objective Response Rate (ORR)
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Chen Xiaoping

Recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

HCC

China
Sun Yat-sen University

Recruiting

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

Liver Tumor

China
Xinrui Zhu

Enrolling by invitation

The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable | Tyrosine Kinase Inhibitor | Transarterial Chemoembolization | Immune Checkpoint Blockade

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Advanced Biliary Tract Cancer

China
Akeso

Not yet recruiting

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
Andalusian School of Public Health

Completed

Effectiveness of Two Interventions in Patients With Low Educational Level With Diabetes to Reduce Inequalities in Self-care Behavior

Diabetes Mellitus Type 2

Spain
Sun Yat-sen University

Recruiting

TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

Hepatocellular Carcinoma

China
Wen Li

Recruiting

HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
IRCCS Centro San Giovanni di Dio Fatebenefratelli
IRCCS San Raffaele; Fondazione Don Carlo Gnocchi Onlus; IRCCS Centro Neurolesi...

Active, not recruiting

Telerehabilitation in Mild Cognitive Impairment

Mild Cognitive Impairment

Italy
University of Kansas Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Texting for Mobility in Overweight/Obese Adults With Peripheral Artery Disease

Overweight and Obesity

United States
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma

Hepatocellular Carcinoma Stage III
Shanghai Zhongshan Hospital

Enrolling by invitation

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Enrolling by invitation

Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Hepatocellular Carcinoma

China
Indiana University

Completed

Adhesive Tape Placement on Patients' Masks in the Emergency Department Increases Compliance of Proper Face Mask Use

Covid19

United States
Sun Yat-sen University

Recruiting

PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial (PLATIC)

Hepatocellular Carcinoma

China
Wen Tianfu

Recruiting

Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)

Advanced Hepatocellular Carcinoma

China
University of North Carolina, Chapel Hill

Completed

Effects of Alpha tACS (PACS)

Healthy
Shenzhen SiBiono GeneTech Co.,Ltd

Unknown

Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)

China
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Advanced Renal Cell Carcinoma
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-013)

Cholangiocarcinoma Non-resectable

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.

Recruiting

Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-011)

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma Non-resectable

China
Chinese PLA General Hospital

Unknown

Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Hepatocellular Carcinoma

China
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Nanfang Hospital, Southern Medical University

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Gastric Cancer

China
Zhejiang Cancer Hospital

Unknown

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)

Carcinoma, Hepatocellular
Sun Yat-sen University

Recruiting

TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC (TACE)

Advanced Hepatocellular Carcinoma

China
Hospital of Macerata

Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)

Italy
Ruijin Hospital

Recruiting

Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer

HER2-negative Advanced Gastric Cancer

China
Peking University Cancer Hospital & Institute

Not yet recruiting

To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases

Colorectal Liver Metastases (CRCLM)

China
Peking Union Medical College Hospital

Completed

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Cholangiocarcinoma | Biomarker | Combinational Immunotherapy | Liver Neoplasm Malignant Primary

China

Search clinical trials for: Lenvatinib plus TACE

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations